X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-03-07 | TVGN | Tevogen Bio Holdings Inc. | Flomenberg Neal | See Remarks | S - Sale | $1.09 | -211,909 | 3,828,576 | -5% | -$231,734 | |||||
2025-03-07 | IMVT | Immunovant, Inc. | Fromkin Andrew J. | Dir | S - Sale | $19.60 | -8,000 | 91,913 | -8% | -$156,769 | ||||||
2025-03-10 | TNYA | Tenaya Therapeutics, Inc. | Higa Tomohiro | SVP, Finance | S - Sale | $0.54 | -2,482 | 99,690 | -2% | -$1,336 | ||||||
2025-03-10 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Chief Medical Officer | S - Sale | $0.54 | -7,398 | 174,793 | -4% | -$3,983 | ||||||
2025-03-10 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | CEO | S - Sale | $0.54 | -9,741 | 320,514 | -3% | -$5,245 | ||||||
2025-03-07 | BIIB | Biogen Inc. | Sherwin Stephen A | Dir | S - Sale | $150.02 | -8,760 | 11,318 | -44% | -$1,314,142 | ||||||
2025-03-06 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $40.91 | -918 | 130,912 | -1% | -$37,558 | ||||||
2025-03-06 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $40.91 | -277 | 111,984 | 0% | -$11,333 | ||||||
| D | 2025-03-06 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $40.91 | -2,402 | 662,692 | 0% | -$98,273 | |||||
2025-03-06 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $40.91 | -241 | 51,434 | 0% | -$9,860 | ||||||
2025-03-05 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $30.48 | -1,590 | 251,033 | -1% | -$48,463 | ||||||
2025-03-05 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $30.15 | -10,000 | 1,292,987 | -1% | -$301,511 | ||||||
| D | 2025-03-05 | TNYA | Tenaya Therapeutics, Inc. | Column Group III Gp, LP | 10% | P - Purchase | $0.70 | +35,714,284 | 58,713,849 | +155% | +$24,999,999 | |||||
| D | 2025-03-05 | TNYA | Tenaya Therapeutics, Inc. | Goeddel David V | Dir, 10% | P - Purchase | $0.70 | +35,714,284 | 58,713,849 | +155% | +$24,999,999 | |||||
| D | 2025-03-05 | PCVX | Vaxcyte, Inc. | Eydelman Mikhail | SVP, GC, Corp Sec | S - Sale+OE | $70.74 | -5,000 | 41,620 | -11% | -$353,699 | |||||
2025-03-05 | MGX | Metagenomi, Inc. | Wein Matthew | See Remarks | S - Sale | $1.87 | -930 | 9,467 | -9% | -$1,744 | ||||||
2025-03-05 | MGX | Metagenomi, Inc. | Wapnick Pamela | CFO | S - Sale | $1.87 | -1,808 | 59,684 | -3% | -$3,390 | ||||||
| DM | 2025-03-05 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $6.48 | -40,000 | 1,256,024 | -3% | -$259,000 | |||||
2025-03-05 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $2.45 | +1,000 | 138,600 | +1% | +$2,450 | ||||||
| M | 2025-03-04 | TVGN | Tevogen Bio Holdings Inc. | Flomenberg Neal | See Remarks | S - Sale | $1.17 | -213,817 | 4,040,485 | -5% | -$250,006 | |||||
| D | 2025-03-05 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $6.99 | -20,875 | 335,346 | -6% | -$145,845 | |||||
| D | 2025-03-05 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale+OE | $6.98 | -26,023 | 347,238 | -7% | -$181,641 | |||||
| D | 2025-03-05 | ADPT | Adaptive Biotechnologies Corp | Benzeno Sharon | Chief Commercial Ofc Imm Med | S - Sale+OE | $6.98 | -44,665 | 392,723 | -10% | -$311,792 | |||||
2025-03-05 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale | $6.98 | -10,320 | 269,010 | -4% | -$72,072 | ||||||
2025-03-05 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres, COO | S - Sale | $6.98 | -59,505 | 588,249 | -9% | -$415,540 | ||||||
2025-03-05 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale | $6.99 | -96,656 | 1,279,524 | -7% | -$675,219 | ||||||
| M | 2025-03-05 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale | $7.29 | -219,569 | 2,959,249 | -7% | -$1,600,417 | |||||
| D | 2025-03-06 | ADPT | Adaptive Biotechnologies Corp | Griffin Michelle Renee | Dir | S - Sale+OE | $7.94 | -15,664 | 51,685 | -23% | -$124,372 | |||||
2025-03-05 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $6.79 | -10,000 | 68,725 | -13% | -$67,900 | ||||||
| D | 2025-03-04 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $7.73 | -395 | 8,012 | -5% | -$3,051 | |||||
| D | 2025-03-04 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $7.73 | -790 | 34,652 | -2% | -$6,103 | |||||
2025-03-05 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.13 | +50,000 | 1,858,029 | +3% | +$6,730 | ||||||
2025-03-03 | EXEL | Exelixis, Inc. | Haley Patrick J. | EVP, Commercial | S - Sale | $38.80 | -10,000 | 375,215 | -3% | -$388,000 | ||||||
| D | 2025-03-04 | DTIL | Precision Biosciences Inc | Smith J. Jefferson | Chief Research Officer | S - Sale+OE | $4.91 | -154 | 95,736 | 0% | -$756 | |||||
| D | 2025-03-04 | DTIL | Precision Biosciences Inc | Scimeca Dario | GC, Secretary | S - Sale+OE | $4.91 | -272 | 25,000 | -1% | -$1,336 | |||||
2025-03-03 | SWTX | Springworks Therapeutics, Inc. | Edris Badreddin | COO | S - Sale | $54.23 | -20,000 | 169,712 | -11% | -$1,084,592 | ||||||
2025-03-03 | SWTX | Springworks Therapeutics, Inc. | Islam Saqib | CEO | S - Sale | $54.24 | -49,000 | 954,869 | -5% | -$2,657,656 | ||||||
2025-03-03 | ATRA | Atara Biotherapeutics, Inc. | Nguyen Anhco | Pres, CEO | S - Sale | $7.00 | -3,331 | 74,123 | -4% | -$23,307 | ||||||
2025-03-03 | ATRA | Atara Biotherapeutics, Inc. | Hyllengren Eric J | EVP, CFO, COO | S - Sale | $7.00 | -1,211 | 56,231 | -2% | -$8,473 | ||||||
2025-03-03 | ATRA | Atara Biotherapeutics, Inc. | Henrich Jill | EVP, Chief Regulatory Officer | S - Sale | $7.00 | -1,059 | 18,679 | -5% | -$7,410 | ||||||
2025-03-04 | EDIT | Editas Medicine, Inc. | Lucera Erick | EVP, CFO | S - Sale | $1.71 | -4,109 | 112,720 | -4% | -$7,030 | ||||||
2025-03-04 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | CEO | S - Sale | $1.71 | -16,632 | 295,474 | -5% | -$28,452 | ||||||
2025-03-04 | EDIT | Editas Medicine, Inc. | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $1.71 | -2,891 | 70,245 | -4% | -$4,946 | ||||||
2025-03-03 | BLUE | Bluebird Bio, Inc. | Colvin Richard A | Chief Medical Officer | S - Sale | $3.92 | -584 | 7,610 | -7% | -$2,289 | ||||||
| D | 2025-03-03 | VCEL | Vericel Corp | Halpin Michael | COO | S - Sale+OE | $49.52 | -10,000 | 15,539 | -39% | -$495,200 | |||||
2025-03-03 | BLUE | Bluebird Bio, Inc. | Klima Thomas J | See Remarks | S - Sale | $3.92 | -500 | 7,878 | -6% | -$1,960 | ||||||
| D | 2025-03-03 | VCEL | Vericel Corp | Hagen Heidi | Dir | S - Sale+OE | $49.53 | -9,000 | 28,650 | -24% | -$445,770 | |||||
2025-03-03 | VCEL | Vericel Corp | Mara Joseph Anthony Jr | CFO | S - Sale | $49.53 | -9,000 | 13,967 | -39% | -$445,770 | ||||||
| D | 2025-03-03 | VCEL | Vericel Corp | Hopper Jonathan Mark | Chief Medical Officer | S - Sale+OE | $49.53 | -10,000 | 66,101 | -13% | -$495,300 | |||||
2025-03-03 | BLUE | Bluebird Bio, Inc. | Obenshain Andrew | Pres, CEO | S - Sale | $3.92 | -921 | 18,327 | -5% | -$3,610 | ||||||
2025-03-03 | ALEC | Alector, Inc. | Kenkare-Mitra Sara | Pres, Head of R, D | S - Sale | $1.47 | -29,073 | 536,142 | -5% | -$42,662 | ||||||
2025-03-03 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $1.47 | -40,330 | 6,397,119 | -1% | -$59,176 | ||||||
2025-03-03 | ALEC | Alector, Inc. | Grasso Marc | CFO | S - Sale | $1.47 | -18,091 | 312,560 | -5% | -$26,547 | ||||||
2025-03-03 | ALEC | Alector, Inc. | Romano Gary | Chief Medical Officer | S - Sale | $1.47 | -16,306 | 332,977 | -5% | -$23,927 | ||||||
2025-03-04 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.12 | +44,000 | 1,808,029 | +2% | +$5,060 | ||||||
| M | 2025-03-03 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $2.30 | +38,289 | 137,600 | +39% | +$88,065 | |||||
2025-03-03 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | P - Purchase | $31.22 | +160,314 | 21,269,463 | +1% | +$5,004,318 | ||||||
2025-03-03 | MRNA | Moderna, Inc. | Sagan Paul | Dir | P - Purchase | $31.76 | +31,620 | 494,133 | +7% | +$1,004,251 | ||||||
2025-03-04 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.12 | +83,334 | 1,764,029 | +5% | +$10,000 | ||||||
2025-03-03 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.11 | +500 | 108,420 | 0% | +$1,055 | ||||||
| D | 2025-03-03 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale+OE | $73.27 | -8,000 | 151,916 | -5% | -$586,165 | |||||
2025-03-03 | HALO | Halozyme Therapeutics, Inc. | Henderson Jeffrey William | Dir | S - Sale | $58.69 | -5,000 | 33,611 | -13% | -$293,458 | ||||||
| D | 2025-03-03 | KYMR | Kymera Therapeutics, Inc. | Chiniara Ellen | GC | S - Sale+OE | $30.45 | -2,241 | 80,085 | -3% | -$68,239 | |||||
| D | 2025-03-03 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale+OE | $30.45 | -1,383 | 67,800 | -2% | -$42,113 | |||||
| D | 2025-03-03 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale+OE | $30.45 | -7,035 | 201,886 | -3% | -$214,219 | |||||
| D | 2025-03-03 | KYMR | Kymera Therapeutics, Inc. | Gollob Jared | Chief Medical Officer | S - Sale+OE | $30.45 | -5,740 | 120,000 | -5% | -$174,786 | |||||
| DM | 2025-02-27 | EXEL | Exelixis, Inc. | Smith Julie | Dir | S - Sale+OE | $38.00 | -73,808 | 10,778 | -87% | -$2,804,459 | |||||
| D | 2025-02-28 | EXEL | Exelixis, Inc. | Wyszomierski Jack L | Dir | S - Sale+OE | $37.80 | -8,768 | 356,605 | -2% | -$331,430 | |||||
| D | 2025-02-27 | KRYS | Krystal Biotech, Inc. | Romano Kathryn | Chief Accounting Officer | S - Sale+OE | $175.22 | -750 | 19,318 | -4% | -$131,415 | |||||
2025-02-26 | CRSP | Crispr Therapeutics AG | Greene John | Dir | P - Purchase | $44.85 | +7,000 | 7,000 | New | +$313,948 | ||||||
| M | 2025-02-26 | ADVM | Adverum Biotechnologies, Inc. | Leonard Braden Michael | 10% | P - Purchase | $4.27 | +336,756 | 2,709,620 | +14% | +$1,439,087 | |||||
| M | 2025-02-25 | HALO | Halozyme Therapeutics, Inc. | Labarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | S - Sale | $58.10 | -21,697 | 173,756 | -11% | -$1,260,681 | |||||
2025-02-25 | CGEM | Cullinan Therapeutics, Inc. | Jones Jeffrey Alan | Chief Medical Officer | S - Sale | $8.53 | -4,895 | 174,164 | -3% | -$41,754 | ||||||
2025-02-25 | CGEM | Cullinan Therapeutics, Inc. | Ahmed Nadim | Pres, CEO | S - Sale | $8.53 | -12,529 | 430,621 | -3% | -$106,872 | ||||||
2025-02-25 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $8.53 | -3,756 | 142,004 | -3% | -$32,039 | ||||||
2025-02-25 | CGEM | Cullinan Therapeutics, Inc. | Sumer Jacquelyn L | GC | S - Sale | $8.53 | -3,756 | 136,895 | -3% | -$32,039 | ||||||
2025-02-26 | VIR | Vir Biotechnology, Inc. | De Verneuil Vanina | EVP, GC | S - Sale | $9.14 | -7,373 | 79,460 | -8% | -$67,402 | ||||||
| D | 2025-02-26 | ACLX | Arcellx, Inc. | Elghandour Rami | SEE REMARKS | S - Sale+OE | $62.02 | -38,300 | 149,186 | -20% | -$2,375,517 | |||||
2025-02-24 | EXEL | Exelixis, Inc. | Haley Patrick J. | EVP, Commercial | S - Sale | $36.98 | -52,636 | 337,497 | -13% | -$1,946,479 | ||||||
| D | 2025-02-25 | EXEL | Exelixis, Inc. | Oliver Bob | Dir | S - Sale+OE | $37.25 | -18,647 | 33,514 | -36% | -$694,601 | |||||
2025-02-24 | EXEL | Exelixis, Inc. | Aftab Dana | CSO, EVP Disc, Trans Research | S - Sale | $36.75 | -26,987 | 517,743 | -5% | -$991,772 | ||||||
| D | 2025-02-24 | EXEL | Exelixis, Inc. | Senner Christopher J. | EVP, CFO | S - Sale+OE | $36.14 | -29,314 | 782,330 | -4% | -$1,059,408 | |||||
| D | 2025-02-25 | VCEL | Vericel Corp | Flynn Sean C. | GC | S - Sale+OE | $52.07 | -1,669 | 756 | -69% | -$86,905 | |||||
| D | 2025-02-25 | VCEL | Vericel Corp | Siegal Jonathan | Principal Accounting Officer | S - Sale+OE | $52.07 | -1,137 | 1,206 | -49% | -$59,204 | |||||
| D | 2025-02-25 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $63.16 | -1,500 | 0 | -100% | -$94,740 | |||||
| M | 2025-02-21 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $42.27 | -1,183 | 51,675 | -2% | -$50,004 | |||||
2025-02-21 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $44.18 | -526 | 112,261 | 0% | -$23,237 | ||||||
2025-02-21 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $44.18 | -1,839 | 267,724 | -1% | -$81,242 | ||||||
2025-02-21 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $44.18 | -618 | 131,830 | 0% | -$27,301 | ||||||
2025-02-21 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $44.18 | -918 | 109,496 | -1% | -$40,554 | ||||||
| D | 2025-02-21 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $44.18 | -2,790 | 665,094 | 0% | -$123,254 | |||||
2025-02-24 | VIR | Vir Biotechnology, Inc. | Scangos George A | Dir | S - Sale | $9.45 | -10,056 | 3,813,528 | 0% | -$95,063 | ||||||
2025-02-24 | VIR | Vir Biotechnology, Inc. | Hanly Ann M. | EVP, CTO | S - Sale | $9.45 | -14,168 | 117,901 | -11% | -$133,936 | ||||||
| D | 2025-02-24 | VIR | Vir Biotechnology, Inc. | Sabatini Brent | SVP, Chief Accounting Officer | S - Sale+OE | $9.45 | -1,562 | 46,627 | -3% | -$14,766 | |||||
| D | 2025-02-24 | VIR | Vir Biotechnology, Inc. | De Backer Marianne | CEO | S - Sale+OE | $9.45 | -16,122 | 902,335 | -2% | -$152,408 | |||||
| D | 2025-02-24 | VIR | Vir Biotechnology, Inc. | De Verneuil Vanina | EVP, GC | S - Sale+OE | $9.45 | -5,140 | 86,833 | -6% | -$48,590 | |||||
| D | 2025-02-24 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale+OE | $63.79 | -10,155 | 37,486 | -21% | -$647,773 | |||||
2025-02-20 | SWTX | Springworks Therapeutics, Inc. | Islam Saqib | CEO | S - Sale | $60.30 | -29,328 | 1,034,625 | -3% | -$1,768,401 | ||||||
2025-02-20 | SWTX | Springworks Therapeutics, Inc. | Ashar Bhavesh | Chief Commercial Officer | S - Sale | $61.19 | -1,016 | 62,053 | -2% | -$62,168 | ||||||
2025-02-20 | SWTX | Springworks Therapeutics, Inc. | Lynch Daniel | Dir | S - Sale | $60.22 | -47,600 | 82,944 | -36% | -$2,866,534 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |